Is Wegovy Approved for Long-Term Weight Maintenance?
Wegovy (semaglutide) is FDA-approved for chronic weight management in adults with obesity or overweight with weight-related conditions, and in children aged 12+ with obesity. Labeling specifies use alongside reduced-calorie diet and increased physical activity, with no fixed duration limit, supporting ongoing treatment as long as benefits outweigh risks.[1][2]
How Long Do Clinical Trials Show It Works?
In the STEP trials, patients on Wegovy maintained weight loss over 68 weeks (about 1.5 years), with average losses of 15-17% body weight versus 2-3% on placebo. Extension studies up to 4 years confirm sustained efficacy, with 80-90% of participants keeping at least 75% of initial loss when continuing therapy.[3][4]
What Happens If You Stop Taking Wegovy?
Discontinuation leads to weight regain in most patients. STEP 1 extension data showed those stopping after 68 weeks regained two-thirds of lost weight within a year, returning near baseline. Ongoing use is needed for maintenance.[3][5]
Doctor and Patient Experiences with Long-Term Use
Prescribers often continue Wegovy indefinitely for maintenance if tolerated, per Endocrine Society guidelines recommending GLP-1 agonists like semaglutide for long-term obesity management. Real-world data from 2+ years shows persistent benefits, though some patients cycle off due to side effects or cost.[6][7]
Common Risks and Side Effects Over Time
Gastrointestinal issues (nausea, diarrhea) decrease after initial months but persist in 10-20%. Long-term concerns include gallbladder disease (2-3% risk), pancreatitis (rare), and potential thyroid tumors (from rodent data, not confirmed in humans). Muscle loss with fat loss prompts monitoring protein intake and exercise. No evidence of new risks beyond 4 years yet.[2][8]
Cost and Access for Ongoing Use
Monthly cost is $1,300-$1,700 without insurance; copay cards reduce to $0-$25 for eligible patients. Medicare covers for obesity in some cases post-2024 rules. Supply shortages have eased, but prior authorizations are common.[9]
Alternatives for Long-Term Weight Maintenance
| Option | Key Comparison to Wegovy |
|--------|--------------------------|
| Zepbound (tirzepatide) | Similar GLP-1 but dual GIP action; up to 21% loss in trials, also for chronic use. |
| Saxenda (liraglutide) | Daily injection; less weight loss (5-10%), approved long-term. |
| Phentermine-topiramate (Qsymia) | Oral pill; 8-10% loss, indefinite use but controlled substance. |
| Bariatric surgery | 20-30% sustained loss; one-time but with lifelong changes. |
| Lifestyle alone | 3-5% loss, harder to maintain without meds. |
All require diet/exercise; surgery for BMI 40+ or 35+ with conditions.[10]
Sources
[1]: FDA Wegovy Label
[2]: Novo Nordisk Prescribing Info
[3]: NEJM STEP 1 Trial
[4]: STEP 5 Extension
[5]: Wilding et al., Diabetes Obes Metab 2022
[6]: Endocrine Society Guidelines
[7]: JAMA Real-World Study
[8]: FDA Adverse Events
[9]: GoodRx Pricing
[10]: AAES Surgery Guidelines